340B Drug Pricing Program Contributes to Rising Healthcare Costs and Is Ripe for Reform
The U.S. House Energy & Commerce Committee's Health Subcommittee today will host the third hearing in its health care affordability series, specifically examining the role providers and hospitals play in shaping the cost of care for Americans.
While the hearing will likely examine numerous issues, there is none more ripe for reform than the flawed 340B drug pricing program.
Originally enacted to help eligible safety-net providers buy medicines at steep discounts and pass the savings on to lower-income and vulnerable patients, the program has ballooned as a revenue stream for many participating hospitals and contract pharmacy chains.
As the size and complexity of the 340B program has expanded, participating hospitals and contract pharmacies have instead used the program to increase…[more]
The Pennsylvania-based U.S. Steel company recently agreed to be purchased by the Tokyo-headquartered publicly traded company Nippon Steel. This deal makes sense to economists. It will encourage other foreign companies to invest in the U.S., creating wealth and new job opportunities, and further shoring up the U.S. economy, particularly amid inflation worries. More importantly, this deal makes sense to the owners of U.S. Steel.
And yet, in our age of government shoving its fingers into everything, President Joe Biden announced that he opposes this purchase for muddled, misguided reasons. Former…
